US 12,168,020 B2
Method for ameliorating, preventing or treating muscular atrophy or sarcopenia by administering composition comprising 2′-fucosyllactose as active ingredient
Yeon Ji Kim, Daegu (KR); Kyung Ho Kim, Daegu (KR); Chul Soo Shin, Suwon-si (KR); Jong Won Yoon, Seongnam-si (KR); Seon Min Jeon, Daegu (KR); Young Ha Song, Yongin-si (KR); Jong Gil Yoo, Suwon-si (KR); and Ji Eun Kim, Hwaseong-si (KR)
Assigned to ADVANCED PROTEIN TECHNOLOGIES CORP., Suwon-si (KR)
Filed by ADVANCED PROTEIN TECHNOLOGIES CORP., Suwon-si (KR)
Filed on Aug. 26, 2022, as Appl. No. 17/896,339.
Application 17/896,339 is a continuation of application No. PCT/KR2021/018900, filed on Dec. 13, 2021.
Claims priority of application No. 10-2021-0162483 (KR), filed on Nov. 23, 2021.
Prior Publication US 2023/0158052 A1, May 25, 2023
Int. Cl. A61K 31/702 (2006.01); A61P 21/06 (2006.01)
CPC A61K 31/702 (2013.01) [A61P 21/06 (2018.01)] 10 Claims
 
1. A method for treating muscular atrophy, the method comprising administering a composition comprising 2′-fucosyllactose (2′-FL) as an active ingredient to a subject in need thereof,
wherein the subject suffers from:
(i) primary muscular atrophy which is induced by a lack of mechanical stimulation, decreased activity of neuromuscular junctions, decreased mitochondrial function, or nutritional deficiency, or
(ii) secondary muscular atrophy which is induced by denervation due to stroke, excessive drug use, or changes in endocrine system hormones and sex hormones,
wherein the subject requires increasing muscle differentiation or increasing a weight of muscle tissue, and
wherein the 2′-fucosyllactose is administered at a dosage of 400 mg/kg/day based on a body weight of the subject.